Lewitt MS et al. (2010), IGF-binding protein 1 and abdominal obesity in ...

ECB-ART-41657

Eur J Endocrinol 2010 Aug 01;1632:233-42. doi: 10.1530/EJE-10-0301.

Show Gene links Show Anatomy links

IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women.

Lewitt MS , Hilding A , Brismar K , Efendic S , Ostenson CG , Hall K .

???displayArticle.abstract???
OBJECTIVE: Low levels of IGF-binding protein 1 (IGFBP1) are associated with metabolic syndrome and predict diabetes development in men. The aim of this study was to determine the levels of IGFBP1 in women who later develop diabetes, in relation to abdominal obesity, and to compare these levels with those of men. METHODS: IGFBP1 levels were determined at baseline and after 8 years in a case-control, prospective study of Swedish women aged 35-56 years. Individuals with normal oral glucose tolerance test (OGTT) who developed abnormal glucose regulation (n=240) were pair matched to controls for age and family history of diabetes and also compared to men of the same age (n=355). RESULTS: Low fasting IGFBP1 and increased waist measurement predicted development of diabetes in women (n=60; odds ratio (OR) 70, 95% confidence interval (CI) 8-661, lowest tertile and OR 27, 95% CI 5-141, highest tertile). In women developing diabetes, baseline IGFBP1 levels were lower than expected for fasting insulin values, were associated with impaired suppression after OGTT and increased during 8 years despite an increase in fasting insulin. All individuals in the highest tertile for waist and with <or=40% suppression of IGFBP1 developed diabetes within 8 years. Circulating IGFBP1 concentrations were higher in women compared to men. Women and men who developed diabetes had a similar degree of abdominal obesity, corrected for height. CONCLUSIONS: We conclude that low IGFBP1 and elevated waist measurement predict diabetes development and that IGFBP1 production is suppressed by a novel factor(s) in women developing diabetes. Increasing levels of IGFBP1 during the emergence of diabetes in men and women suggest the emergence of hepatic insulin resistance.

???displayArticle.pubmedLink??? 20508082
???displayArticle.pmcLink??? PMC2909736
???displayArticle.link??? Eur J Endocrinol

Genes referenced: LOC100889856 LOC100893907 LOC105439578 LOC105439585 LOC593945

???attribute.lit??? ???displayArticles.show???

References [+] :

Bang, Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. 1991, Pubmed
Cardim, The insulin-like growth factor-I system and hormone replacement therapy. 2001, Pubmed
Colditz, Weight gain as a risk factor for clinical diabetes mellitus in women. 1995, Pubmed
Conover, Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. 1992, Pubmed
Diel, Identification of estrogen regulated genes in Fe33 rat hepatoma cells by differential display polymerase chain reaction and their hormonal regulation in rat liver and uterus. 1995, Pubmed
Dotevall, Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA study. 2004, Pubmed
Eriksson, Psychological distress and risk of pre-diabetes and Type 2 diabetes in a prospective study of Swedish middle-aged men and women. 2008, Pubmed
Gibson, Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). 1996, Pubmed
Heald, Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. 2001, Pubmed
Herbert, Coated charcoal immunoassay of insulin. 1965, Pubmed
Hilding, Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. 1995, Pubmed
Kalme, Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. 2005, Pubmed
Kotronen, Effect of liver fat on insulin clearance. 2007, Pubmed
Kotronen, Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. 2008, Pubmed
Laakso, Prevention of type 2 diabetes. 2005, Pubmed
Laughlin, The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. 2004, Pubmed
Lee, Insulin-like growth factor binding protein-1: recent findings and new directions. 1997, Pubmed
Lee, Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. 2008, Pubmed
Legato, Gender-specific care of the patient with diabetes: review and recommendations. 2006, Pubmed
Lewitt, Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. 2008, Pubmed , Echinobase
Mogul, Insulin like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women. 1996, Pubmed
Paassilta, Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. 2000, Pubmed
Petersson, Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Söderåkra Cardiovascular Risk Factor Study. 2009, Pubmed
Póvoa, Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. 1984, Pubmed
Rajpathak, Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. 2008, Pubmed
Regitz-Zagrosek, Gender differences in the metabolic syndrome and their role for cardiovascular disease. 2006, Pubmed
Steinbaum, The metabolic syndrome: an emerging health epidemic in women. 2004, Pubmed
Suikkari, Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. 1989, Pubmed
Suikkari, Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. 1991, Pubmed
Veldhuis, Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I/IGFBP-1 concentrations. 2005, Pubmed
Weaver, Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity. 1990, Pubmed
Yeoh, Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. 1988, Pubmed

	Figure 1. Study design: selection and follow-up of women in the Stockholm Diabetes Prevention Programme. The groups from which the present study population was derived were categorized according to 1999 WHO criteria and are shown in bold type. FHD+, family history of diabetes; FHD−, no family history of diabetes; GDM, history of gestational diabetes; T2DM, type 2 diabetes mellitus. Exclusion criteria: already known diabetes (1.5%), unclear FHD (28.5%), insufficient FHD according to inclusion criteria (9.9%), foreign origin (7.6%), moved or deceased (2.0%). *Subjects aged 35–44 years born in the last third of each month were excluded for financial reasons.


	Figure 4. ORs (95% CIs) of variables for the development of IGT (a), IFG or IFG+IGT (b) and type 2 diabetes (c) in women. The lowest tertile was used as the reference in the calculation. Note that the inverse of IGFBP1 was used. f, fasting.
	Figure 5. Relationship between the change in fasting IGFBP1 and the change in fasting insulin (a) or the change in IGF1 (b) in women developing diabetes at 8-year follow-up. The individuals developing diabetes (n=60) are represented by the solid circles and unbroken regression lines, and are compared with their matched controls, which are represented by the open circles and broken regression lines. Correlation coefficients: (a) controls: r=−0.54, P<0.001; diabetes: r=−0.16, P=0.212; (b) controls: r=−0.20, P=0.117; diabetes: r=−0.52, P<0.001.